Related Experiment Videos
NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis
1Department of Internal Medicine, University Hospital of Zurich, Switzerland. hausmann@usz.ch
Zeitschrift Fur Gastroenterologie
|March 7, 2008
Summary
Genetic variations in NAT1 do not predict treatment response or side effects to 5-aminosalicylic acid (5-ASA) in ulcerative colitis (UC) patients. Non-genomic factors may influence clinical outcomes with 5-ASA therapy.
Area of Science:
- Pharmacogenomics
- Gastroenterology
- Molecular Biology
Background:
- 5-Aminosalicylic acid (5-ASA) metabolism in ulcerative colitis (UC) is influenced by N-acetyltransferase 1 (NAT1) acetylation activity.
- Genetic polymorphisms in NAT1 can lead to rapid or slow acetylation, potentially affecting 5-ASA efficacy and side effects.
- Up to 10% of UC patients experience adverse events during 5-ASA treatment.
Purpose of the Study:
- To investigate the association between NAT1 genetic variations and clinical response to 5-ASA in UC patients.
- To determine if NAT1 genotypes can predict treatment efficacy and the occurrence of side effects.
Main Methods:
- DNA analysis of 78 UC patients, including NAT1 genotyping for known alleles using RFLP and sequence analysis.
- Clinical response to 5-ASA was assessed via medical record review.
- Correlation analysis between NAT1 genotypes and patient outcomes (remission vs. active disease, side effects).
Main Results:
- Four NAT1 alleles (*3, *4, *10, *11) were identified in the UC cohort.
- Prevalence of specific genotypes: NAT1*10 (31% heterozygous, 4% homozygous), NAT1*3 (6% heterozygous), NAT1*11 (6% heterozygous).
- No statistically significant association was found between NAT1 genotype and clinical response or side effects to 5-ASA.
Conclusions:
- NAT1 genotypes do not serve as reliable predictors for 5-ASA response or side effects in UC.
- Non-genomic factors may play a significant role in determining individual clinical responses to 5-ASA therapy.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...